Tuesday, October 12th, 2010 - Raltitrexed (Tomudex®) in Combination With Cisplatin in the Treatment of MPM Improves Overall Survival Compared to Treatment With Cisplatin Alone
Archive for the 'Drug Companies' Category
Tuesday, April 20th, 2010 - MolMed starts Phase III trial of NGR-hTNF in mesothelioma
Tuesday, April 13th, 2010 - microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications
Friday, March 26th, 2010 - Bionomics To Initiate BNC105 Phase II Trial In Mesothelioma Patients
Thursday, February 18th, 2010 - Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients
Monday, August 10th, 2009 - Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada
Monday, April 13th, 2009 - Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
Monday, December 29th, 2008 - Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Friday, October 10th, 2008 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
Friday, June 6th, 2008 - The European Commission Grants Orphan Drug Designation for Molmed’s Vascular Targeting Agent Arenegyr in the Treatment of Mesothelioma
Thursday, May 29th, 2008 - Arenegyr: Key Preliminary Results of Phase II Trials in Mesothelioma and Colorectal Cancer Presented at ASCO
Thursday, May 29th, 2008 - Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint
Friday, May 16th, 2008 - Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Wednesday, April 2nd, 2008 - Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Friday, January 18th, 2008 - Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
